← Eichor
Condition: Anlotinib Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Anlotinib

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurr
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07520760Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer
Phase 1 · 1 location(s) · Fudan University · NCT06331169Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC
Phase 2 · 1 location(s) · Fudan University · NCT05229003Metastatic Nasopharyngeal Carcinoma
Phase 1 · 1 location(s) · Chen Xiaozhong · NCT06886347SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer
NA · 1 location(s) · The First People's Hospital of Lianyungang · NCT06476093Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.
Phase 3 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07443397First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma
Phase 2 · 2 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT05188859The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer
Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT05075512Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT07025174A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Th
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07358676Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW
Phase 2 · 1 location(s) · Hunan Province Tumor Hospital · NCT06355609A Clinical Trial of Furmonertinib Combined With Anlotinib as First-line Treatment for Advanced NSCLC With EGFR-sensitive
Phase 2 · 1 location(s) · Henan Cancer Hospital · NCT06945705A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastati
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07455019Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)
Phase 2 · 3 location(s) · First Affiliated Hospital of Zhejiang University · NCT06874933Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients
Phase 2 · 1 location(s) · Jiangxi Provincial Cancer Hospital · NCT05252078Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT
Phase 2 · 1 location(s) · JIANYANG WANG · NCT07037680Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma
Phase 2 · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT05214222Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (AP
Phase 3 · 24 location(s) · Advenchen Laboratories, LLC · NCT03016819Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma
Phase 1/Phase 2 · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT06970145XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT05494060MAGNATE-S: Paclitaxel Polymer Micelles Combo in Advanced Sarcoma
Phase 2 · 1 location(s) · Shanghai 6th People's Hospital · NCT07359053Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Che
Phase 3 · 71 location(s) · Shanghai Chia Tai Tianqing Pharmaceutical Technology Develop · NCT07165951A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of
Phase 2 · 10 location(s) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · NCT05913089Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma
Phase 4 · 19 location(s) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · NCT05830500QL1706 Combined With Chemotherapy and Anlotinib for the Treatment of Recurrent Ovarian Cancer
Phase 2 · 1 location(s) · Affiliated Cancer Hospital & Institute of Guangzhou Medical · NCT07286240Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Che
Phase 2 · 5 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06141226Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma
Phase 2 · 1 location(s) · Ming-Yuan Chen · NCT07581821QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in
Phase 2 · 1 location(s) · Jiangsu Cancer Institute & Hospital · NCT07601178A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Rec
Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT07330544Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC)
Phase 2 · 1 location(s) · Shanghai Changzheng Hospital · NCT04278222
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.